Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
193
days
IAP inhibition enhances response to radiotherapy and chemotherapy in preclinical models of rectal cancer
Authors
Timothy O’Brien; Thomas Wright; Matilda Downs; Shaun Sharkey; Catherine Higgins; Jaine Blayney; Fiza M.F. Ishaqwala; Liang Tang; Ashley K. McCulloch; Chia Y. Kong; Lily V.S. Hillson; Ross K. McMahon; Sean M. O’Cathail; Kathryn Pennel; Joanne Edwards; Karl Butterworth; Tomoko Smyth; George Ward; Melissa LaBonte-Wilson; Simon McDade; Catherine Hanna; Campbell Roxburgh; Victoria M. Coyle; Daniel B LongleyShow moreShow less
Affiliations
Johnston Cancer Research Centre, Queen’s University Belfast, Northern Ireland, UK; School of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, Scotland, UK; Astex Pharmaceuticals, Cambridge, UKShow moreShow less
160
days
Sexual dysfunction in men after radiotherapy for squamous cell carcinoma of the Anus: A danish anal cancer group DACG study
Authors
Mette J. Krogstrup; Johanne H. Steffensen; Eva Serup-Hansen; Camilla J.S. Kronborg; Karen-Lise G. SpindlerShow moreShow less
Affiliations
Department of Experimental Clinical Oncology, Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus, 8200, Denmark; Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark; Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Borgmester Ib Juuls Vej 9, Herlev, 2730, Denmark; Danish Centre for Particle Therapy, Aarhus University Hospital, Palle Juul-Jensens Boulevard 25, Aarhus N, DK-8200, Denmark; Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus, 8200, DenmarkShow moreShow less
70
days
Cognitive outcomes of low-dose whole-brain radiation therapy in mild Alzheimer's disease: A multicenter, randomized, sham-controlled phase II clinical trial
Authors
Eun-Hee Hong; Aryun Kim; Keun You Kim; Hak Young Rhee; Dong-Ick Shin; Ji Young Kim; Seong-Jun Cho; Dong-Yun Kim; Geon-Ho Jahng; Hyo Been Lee; Woo-Yoon Park; Byoung Hyuck Kim; Weon Kuu ChungShow moreShow less
Affiliations
Radiation Effects Research Section, Radiation Health Institute, Korea Hydro & Nuclear Power Co., Ltd., Seoul, the Republic of Korea; Department of Neurology, College of Medicine, Chungbuk National University, Cheongju, the Republic of Korea; Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, the Republic of Korea; Department of Neurology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, the Republic of Korea; Department of Radiation Oncology, Korea University College of Medicine, Korea University Anam Hospital, Seoul, the Republic of Korea; Department of Radiology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, the Republic of Korea; Healthcare Big Data Center, Medical Science Research Institute, Kyung Hee University Hospital at Gangdong, Seoul, the Republic of Korea; Department of Radiation Oncology, College of Medicine, Chungbuk National University, Cheongju, the Republic of Korea; Department of Radiation Oncology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, the Republic of Korea; Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, the Republic of KoreaShow moreShow less
80
days
DAG-informed analysis of muscle characteristics and overall survival in patients receiving radical treatment for bladder cancer
Authors
Alexander J. Vickers; Donal M. McSweeney; Ananya Choudhury; Jamie Weaver; Craig Jones; James Dyer; Gareth Price; Alan McWilliamShow moreShow less
Affiliations
The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, United Kingdom; Stockport NHS Foundation Trust, Stockport, United KingdomShow moreShow less
63
days
Repeated metastasis-directed radiotherapy in patients with oligorecurrent prostate cancer: outcomes and risk stratification from a large multinational PSMA PET-guided cohort
Authors
Ruth van der Walle; Tessa D. van Bergen; Marcin Miszczyk; Max Peters; Mateusz Bilski; Giulio Francolini; Pietro Garlatti; Maris Mezeckis; Justyna Kociolek; Frederik R. Teunissen; Paulien G. Westhoff; Arthur J.A.T. Braat; Cornelis A.T. van den Berg; Shahrokh F. Shariat; Wietse S.C. Eppinga; Shafak Aluwini; Timo F.W. SoeterikShow moreShow less
Affiliations
University Medical Centre Groningen, Dept. Of Radiation Oncology, Groningen, The Netherlands; Computational Imaging Group for MR Diagnostics and Therapy, Center for Image Sciences, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum – Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland; Department of Radiation Oncology, Radiotherapiegroep, Deventer, The Netherlands; Radiotherapy Department, Affidea Nu-med Center of Oncological Diagnostics and Therapy, Zamosc, Poland; Clinics of Radiotherapy, Medical University of Lublin, Poland; Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy; University of Latvia, Sigulda Hospital Centre of Stereotactic Radiosurgery, Sigulda, Latvia; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; University Medical Centre Utrecht, Dept. of Nuclear Medicine, Utrecht, The Netherlands; University Medical Centre Utrecht, Dept. of Radiation Oncology, Utrecht, The Netherlands; Department of Urology, University of Texas Southwestern, Dallas, USA; Hourani Center for Applied Scientific Research, l-Ahliyya Amman University, Amman, JordanShow moreShow less
168
days
Parametric delineation of the clinical target volume for glioma: Model-based approach that tailors to physician contouring practices
Authors
Gregory Buti; Ali Ajdari; Christopher Bridge; Ariel E. Marciscano; Gregory C. Sharp; Kevin Oh; Fredrik Löfman; Helen A. Shih; Thomas BortfeldShow moreShow less
Affiliations
Massachusetts General Hospital/Mass General Brigham and Harvard Medical School, Department of Radiation Oncology, 100 Blossom St, Boston, MA 02114, USA; Massachusetts General Hospital/Mass General Brigham and Harvard Medical School, Athinoula A. Martinos Center for Biomedical Imaging, 149 Thirteenth St, Charlestown, MA 02129, USA; RaySearch Laboratories AB, Eugeniavägen 18C, SE-104 30 Stockholm, Sweden; Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USAShow moreShow less
FAQ
How long does RADIOTHERAPY AND ONCOLOGY take to review a manuscript?
As of 2026-11-13, CrushSCI has 15 complete review records for RADIOTHERAPY AND ONCOLOGY. The fastest paper went from submission to acceptance in 41 days (When progression-free survival fails to inform: the need for event-level reporting in oligometastatic radiotherapy trials, received 2026-07-13, accepted 2026-08-23); the slowest took 193 days. The average is 113.4 days and the median is 107 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
